{
    "title": "Clinical Trials Modernization Act of 2015",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Clinical Trials Modernization Act of \n2015''.\n\nSEC. 2. CLINICAL TRIAL MODERNIZATION.\n\n    (a) Proposals for Use of Innovative Statistical Methods in Clinical \nProtocols for Drugs, Biological Products, and Devices.--Chapter V of \nthe Federal Food, Drug, and Cosmetic Act is amended by inserting after \nsection 506F (21 U.S.C. 356f) the following new section:\n\n``SEC. 507. CLINICAL TRIAL MODERNIZATION.\n\n    ``(a) In General.--To promote the efficiency of the development and \nregulatory review and approval, licensure, or clearance of drugs, \nbiological products, and devices and the timely availability of \ninnovative treatments, the Secretary shall, after providing notice and \nan opportunity for public comment, establish and implement a framework \nthrough which--\n            ``(1) sponsors of drugs, biological products, or devices \n        may submit to the Secretary a proposal for the incorporation of \n        adaptive trial designs, Bayesian methods, or other alternative \n        statistical methods into proposed clinical protocols and \n        marketing applications for drugs, biological products, or \n        devices; and\n            ``(2) the Secretary will commit to timelines for reviewing \n        and providing feedback on proposals so submitted.''.\n    (b) Guidance Addressing Use of Adaptive Trial Designs and Bayesian \nMethods.--\n            (1) In general.--The Secretary of Health and Human \n        Services, acting through the Commissioner of Food and Drugs (in \n        this subsection referred to as the ``Secretary''), shall--\n                    (A) update and finalize the draft guidance \n                addressing the use of adaptive trial design for drugs \n                and biological products; and\n                    (B) issue draft guidance on the use of Bayesian \n                methods in the development and regulatory review and \n                approval, licensure, or clearance of drugs, biological \n                products, and devices.\n            (2) Contents.--The guidances under paragraph (1) shall--\n                    (A) establish or clarify standards for using \n                adaptive trial designs and Bayesian methods in clinical \n                trials, including clinical trials that form the primary \n                basis for approval, clearance, or licensure of the \n                products involved (such as trials that provide \n                substantial evidence for the approval of drugs);\n                    (B) establish a mechanism for sponsors to obtain \n                feedback from the Secretary under section 507, as added \n                by subsection (a), on technical issues related to \n                modeling and simulations prior to--\n                            (i) completion of such modeling or \n                        simulations; or\n                            (ii) the submission of resulting \n                        information to the Secretary;\n                    (C) specify the types of quantitative and \n                qualitative information required for review; and\n                    (D) specify the recommended analysis methodology.\n            (3) Public meeting.--Prior to updating or developing the \n        guidances required by paragraph (1), the Secretary shall \n        consult, through a public meeting to be held no later than 1 \n        year after the date of enactment of this Act, with stakeholders \n        including representatives of regulated industry, academia, \n        patient advocacy organizations, and disease research \n        foundations.\n            (4) Schedule.--The Secretary shall, after providing notice \n        and opportunity for public comment, publish--\n                    (A) the final guidance required by paragraph (1)(A) \n                not later than 6 months after the date of the public \n                meeting required by paragraph (3); and\n                    (B) the guidance required by paragraph (1)(B) not \n                later than 12 months after the date of the public \n                meeting required by paragraph (3).\n            (5) Review and revision of guidance documents.--Not later \n        than 48 months after the date of enactment of this Act, the \n        Secretary shall review and, as appropriate, revise the guidance \n        documents required by subparagraphs (A) and (B) of paragraph \n        (1) to reflect developments in statistical methods that could \n        be appropriate for use in clinical trials, including clinical \n        trials that--\n                    (A) form the primary basis for approval, clearance, \n                or licensure of drugs, biological products or devices; \n                or\n                    (B) provide substantial evidence for the approval \n                of drugs.\n\nSEC. 3. EVALUATIONS OF REQUIRED POSTAPPROVAL STUDIES AND CLINICAL \n              TRIALS.\n\n    (a) In General.--Section 505(o)(3) of the Federal Food, Drug, and \nCosmetic Act (21 U.S.C. 355(o)(3)) is amended by adding at the end the \nfollowing new subparagraph:\n                    ``(G) Evaluations of required postapproval studies \n                and clinical trials.--\n                            ``(i) In general.--The Secretary shall \n                        establish a process under which the Secretary, \n                        on the initiative of the Secretary or at the \n                        request of a responsible person, shall \n                        periodically evaluate a postapproval study or \n                        clinical trial required to be conducted under \n                        this paragraph to determine whether--\n                                    ``(I) the trial or study is no \n                                longer scientifically warranted; or\n                                    ``(II) the design, or the timelines \n                                applicable to the completion of, the \n                                study or trial should be renegotiated \n                                because of changes in medical practice \n                                or the standard of care.\n                            ``(ii) Not scientifically warranted.--In \n                        the case of a determination under clause (i)(I) \n                        that a postapproval study or clinical trial \n                        required to be conducted under this paragraph \n                        is no longer scientifically warranted, the \n                        Secretary shall no longer require the \n                        responsible person to conduct the study or \n                        trial.\n                            ``(iii) Renegotiation.--In the case of a \n                        determination under clause (i)(II) that the \n                        design, or the timelines applicable to the \n                        completion of, a postapproval study or clinical \n                        trial required to be conducted under this \n                        paragraph should be renegotiated, the Secretary \n                        shall enter into negotiations with the \n                        responsible person to make such changes as may \n                        be necessary to such design or timelines as the \n                        Secretary determines are necessary.''.\n    (b) Guidance.--Not later than one year after the date of the \nenactment of this Act, the Secretary shall issue draft guidance on the \nimplementation of subparagraph (G) of section 505(o)(3) of the Federal \nFood, Drug, and Cosmetic Act (21 U.S.C. 355(o)(3)), as added by \nsubsection (a). Not later than two years after such date of enactment, \nthe Secretary shall issue final guidance on such implementation."
}